National Cancer Institute (NCI): Multiple Myeloma trials

The registry lists 135 Multiple Myeloma studies with National Cancer Institute (NCI) as lead sponsor. 11 are open to participants now and 64 have results posted.

Phase 1 43Phase 2 85Phase 3 7No phase 12(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse EventEnrolling by invitationNCT07499128Not applicable
• Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After TreatmentRecruitingNCT07463807Phase 1/2
• Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First RelapseRecruitingNCT06948084Phase 2
• Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic MalignanciesRecruitingNCT06904066Phase 1
• Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple MyelomaRecruitingNCT06465316Phase 1
• 18F-Fluciclovine PET/CT in Multiple MyelomaRecruitingNCT06103838Phase 2
• Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerRecruitingNCT03412877Phase 2
• Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy ProtocolsRecruitingNCT02682667
• Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell StudiesEnrolling by invitationNCT02473757
• Tissue Collection for Studies of Lymph CancerRecruitingNCT01676805
• Collection of Tissue Samples for Cancer ResearchRecruitingNCT00900198
• Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)Active, not recruitingNCT06400251Phase 2Results posted
• Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)Active, not recruitingNCT06400238Phase 2Results posted
• Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)Active, not recruitingNCT06390852Phase 2Results posted
• Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)Active, not recruitingNCT06390826Phase 2Results posted
• Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)Active, not recruitingNCT06385483Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)Active, not recruitingNCT06360575Phase 2Results posted
• Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)Active, not recruitingNCT06357988Phase 2Results posted
• Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)Active, not recruitingNCT06357975Phase 2Results posted
• Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)Active, not recruitingNCT06308822Phase 2Results posted
• Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)Active, not recruitingNCT06303167Phase 2Results posted
• Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)Active, not recruitingNCT05490771Phase 2Results posted
• A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor TherapyCompletedNCT04847050Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)Active, not recruitingNCT04439357Phase 2Results posted
• Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)Active, not recruitingNCT04439344Phase 2Results posted
• Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)Active, not recruitingNCT04439331Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)Active, not recruitingNCT04439318Phase 2Results posted
• Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingNCT04439292Phase 2Results posted
• Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)Active, not recruitingNCT04439279Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)Active, not recruitingNCT04439266Phase 2Results posted
• Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)Active, not recruitingNCT04439253Phase 2Results posted
• Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)CompletedNCT04439240Phase 2Results posted
• Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)Active, not recruitingNCT04439227Phase 2Results posted
• Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D)CompletedNCT04439214Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)Active, not recruitingNCT04439188Phase 2Results posted
• Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)Active, not recruitingNCT04439175Phase 2Results posted
• Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)Active, not recruitingNCT04439149Phase 2Results posted
• Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
• Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)Active, not recruitingNCT04439123Phase 2Results posted
• Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)Active, not recruitingNCT04439110Phase 2Results posted
• T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple MyelomaCompletedNCT03958656Phase 1Results posted
• Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM TrialCompletedNCT03941860Phase 3Results posted
• Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple MyelomaTerminatedNCT03910439Phase 2Results posted
• Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to TreatmentCompletedNCT03770260Phase 1Results posted
• T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple MyelomaCompletedNCT03602612Phase 1Results posted
• Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple MyelomaTerminatedNCT03031730Phase 1Results posted
• Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell TransplantationCompletedNCT02356159Phase 1/2Results posted
• Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple MyelomaCompletedNCT02215967Phase 1Results posted
• Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01989598Phase 2Results posted
• Lenalidomide Maintenance Therapy for Multiple MyelomaTerminatedNCT01675141Phase 2Results posted
• Carfilzomib and Stem Cell Transplant for Plasma Cell MyelomaTerminatedNCT01658904Phase 1/2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple MyelomaCompletedNCT01572480Phase 2Results posted
• Collection of Transplant Stem Cells for Plasma Cell MyelomaCompletedNCT01547806Phase 2Results posted
• Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple MyelomaCompletedNCT01447914Phase 2Results posted
• Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma PatientsCompletedNCT01402284Phase 2Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• A Phase II Trial of Anti-KIR in Smoldering Multiple MyelomaTerminatedNCT01248455Phase 2Results posted
• Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple MyelomaTerminatedNCT01239368Phase 1/2Results posted
• Imaging in MGUS, SMM and MMCompletedNCT01237054Phase 2Results posted
• Dinaciclib in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01096342Phase 2Results posted
• AZD6244 (Selumetinib) in Treating Patients With Multiple MyelomaCompletedNCT01085214Phase 2Results posted
• Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell TransplantTerminatedNCT01078441Phase 2Results posted
• Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell TransplantationTerminatedNCT00984165Phase 2Results posted
• Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00719901Phase 1/2Results posted
• Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00602641Phase 3Results posted
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With DexamethasoneTerminatedNCT00522392Phase 3Results posted
• Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune SystemCompletedNCT00520130Phase 1/2Results posted
• Sunitinib in Treating Patients With Relapsed Multiple MyelomaCompletedNCT00514137Phase 2Results posted
• Aflibercept for Relapsed Multiple MyelomaTerminatedNCT00437034Phase 2Results posted
• Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple MyelomaCompletedNCT00410605Phase 2Results posted
• Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell TransplantActive, not recruitingNCT00114101Phase 3Results posted
• Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
• Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering MyelomaCompletedNCT00099047Phase 2Results posted
• Bortezomib in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00075881Phase 2Results posted
• Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple MyelomaCompletedNCT00006184Phase 2Results posted
• Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple MyelomaSuspendedNCT06876142Phase 1/2
• Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)WithdrawnNCT06400264Phase 2
• Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)Active, not recruitingNCT06400225Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)Active, not recruitingNCT06390865Phase 2
• Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)Active, not recruitingNCT06385496Phase 2
• Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple MyelomaSuspendedNCT06179888Phase 2
• Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple MyelomaActive, not recruitingNCT06169215Phase 2
• Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing SurgerySuspendedNCT04955808
• Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple MyelomaActive, not recruitingNCT04933539Phase 2
• Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)WithdrawnNCT04439305Phase 2
• National Cancer Institute "Cancer Moonshot Biobank"Active, not recruitingNCT04314401
• Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple MyelomaWithdrawnNCT03856112Phase 1/2
• CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple MyelomaActive, not recruitingNCT03798678Phase 1
• Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT03701321Phase 1/2
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Active, not recruitingNCT02465060Phase 2
• Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV InfectionTerminatedNCT02109224Phase 1
• Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT02101944Phase 1
• Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
• Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01711528Phase 1
• MLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaWithdrawnNCT01660997Phase 2
• Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
• Imaging Studies and the Development of Multiple MyelomaWithdrawnNCT01571726Phase 2
• Viral Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01533194Phase 1
• Providing Access to Cord Blood Units for TransplantsWithdrawnNCT01479582Phase 2
• Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple MyelomaCompletedNCT01330173Phase 1